Franz Gabor

Prof. Dr. Franz Gabor


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2004 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
FGFranz Gabor
Franz Gabor
EBElisabeth Bogner
Elisabeth Bogner
AWAndrea Weissenboeck
Andrea Weissenboeck
MWMichael Wirth
Michael Wirth

1 November 1998 in Journal of Controlled Release
Verified
Journal Article
Closed access
FGFranz Gabor
Franz Gabor
MSMartina Stangl
Martina Stangl
MWMichael Wirth
Michael Wirth

1 January 2007 in BMC Molecular Biology
Verified
Journal Article
Open access
PDF file
STStefan Toegel
Stefan Toegel
WHWenwen Huang
Wenwen Huang
CPClaudia Piana
Claudia Piana
FUFrank M Unger
Frank M Unger
MWMichael Wirth
Michael Wirth
Helmut ViernsteinHelmut Viernstein
Helmut Viernstein
Chondroprotective agents (CPA) such as glucosamine, curcumin and diacerein represent potential remedies for the management of osteoarthritis and several studies have been performed on their effects in-vitro and in-vivo. For the investigation of chondroprotective action on chondrocyte gene expression, quantitative real-time RT-PCR is the method of choice. However, validation of applied normalization strategies represents a crucial and sometimes neglected step in the analysis process. Therefore, the present study aimed to determine the expression stability of common reference genes (ACTB, Beta actin; GAPDH, Glyceraldehyde-3-phosphate; B2M, Beta-2-microglobulin; HPRT1, Hypoxanthine phosphoribosyl-transferase I; SDHA, Succinate dehydrogenase complex, subunit A; YWHAZ, Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide) under the influence of glucosamine, curcumin and diacerein in the IL-1β-stimulated C-28/I2 chondrocyte model, using the geNorm software tool.

1 May 2020 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
JGJulia Clara Gausterer
Julia Clara Gausterer
NSNodir Saidov
Nodir Saidov
NANavid Ahmadi
Navid Ahmadi
CZChengjing Zhu
Chengjing Zhu
MWMichael Wirth
Michael Wirth
CHClemens Honeder
Clemens Honeder

6 July 2009 in Lab on a Chip
Verified
Journal Article
Closed access
PDF file
CFChristian Fillafer
Christian Fillafer
GRGerda Ratzinger
Gerda Ratzinger
JNJürgen Neumann
Jürgen Neumann
ZGZeno Guttenberg
Zeno Guttenberg
SDSilke Dissauer
Silke Dissauer
MSMatthias F. Schneider
Matthias F. Schneider
The interaction of targeted drug carriers with epithelial and endothelial barriers in vivo is largely determined by the dynamics of the body fluids. To simulate these conditions in binding assays, a fully biocompatible in vitro model was developed which can accurately mimic a wide range of physiological flow conditions on a thumbnail-format cell-chip. This acoustically-driven microfluidic system was used to study the interaction characteristics of protein-coated particles with cells. Poly(D,L-lactide-co-glycolide) (PLGA) microparticles (2.9 ± 1 µm) were conjugated with wheat germ agglutinin (WGA-MP, cytoadhesive protein) or bovine serum albumin (BSA-MP, non-specific protein) and their binding to epithelial cell monolayers was investigated under stationary and flow conditions. While mean numbers of 1500 ± 307 mm−2 WGA-MP and 94 ± 64 mm−2 BSA-MP respectively were detected to be cell-bound in the stationary setup, incubation at increasing flow velocities increasingly antagonized the attachment of both types of surface-modified particles. However, while binding of BSA-MP was totally inhibited by flow, grafting with WGA resulted in a pronounced anchoring effect. This was indicated by a mean number of 747 ± 241 mm−2 and 104 ± 44 mm−2 attached particles at shear rates of 0.2 s−1 and 1 s−1 respectively. Due to the compactness of the fluidic chip which favours parallelization, this setup represents a highly promising approach towards a screening platform for the performance of drug delivery vehicles under physiological flow conditions. In this regard, the flow-chip is expected to provide substantial information for the successful design and development of targeted micro- and nanoparticulate drug carrier systems.

1 May 2003 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
NLNina Lochner
Nina Lochner
FPFritz Pittner
Fritz Pittner
MWMichael Wirth
Michael Wirth
FGFranz Gabor
Franz Gabor